Business
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuti...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, CanadaToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv® (treosulfan for injection) to be listed on the BC Cancer Benefit Drug List and funded through BC Cancer, a part of PHSA that provides a province-wide population-based cancer control program for the residents of British Columbia. BC Cancer will now reimburse eligible claims made for Trecondyv® for eligible patients in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies.*\"This important reimbursement milestone is the first of several we expect following the successful completion of the pCPA negotiation process for Trecondyv®,\" said Richard Labelle, Medexus's Chief Operating Officer. \"It demonstrates our commitment to seeking and quickly achieving public reimbursement of Trecondyv® across Canada, and is yet another important indicator of this product's prospects and potential, both in the Canadian market and, if and when approved by the FDA, the US market as well.\"The next step in the Trecondyv® public reimbursement process will be for other remaining government organizations to make their respective final decisions on public reimbursement for their regions or jurisdictions. Medexus is committed to continuing to work with these other participating provincial, territorial, and federal government organizations to make Trecondyv® available as soon as possible through public drug plans for the patients who need it.* BC Cancer, \"BC Cancer Benefit Drug List: January 2025,\" available at www.bccancer.bc.ca/systemic-therapy-site/documents/policy%20and%20forms/benefit%20drug%20list.pdf (HTTPS version not available) (accessed January 14, 2025).About Trecondyv® (treosul...